Blis K12 Streptococcus Salivarius
Also known as: BLIS K12, *Streptococcus salivarius* K12
Overview
BLIS K12, a probiotic strain isolated from the oral cavity of a healthy child, is categorized as *Streptococcus salivarius* K12. It is naturally present in a minority of the population and is notable for its production of bacteriocins like salivaricin A2 and B, which play a role in oral health and immune function. The primary applications of BLIS K12 include the prevention of conditions such as pharyngitis, pharyngotonsillitis, and acute otitis media, in addition to promoting oral health through the reduction of halitosis and enhancement of immune response. The evidence for its efficacy and safety is moderate, supported by a range of clinical trials indicating beneficial outcomes, although further systematic reviews are needed for a thorough understanding.
Benefits
Research indicates that BLIS K12 significantly reduces both the incidence and severity of pharyngitis and pharyngotonsillitis. Some studies have shown reductions in days of missed school or work due to illness, providing a valuable option for children with recurrent streptococcal infections. Additionally, it can alleviate oral mucositis in patients undergoing head and neck radiotherapy. Evidence also suggests a potential role in reducing halitosis by inhibiting bacteria that create volatile sulfur compounds. While the effect size varies, benefits can often be observed within days of initiation with effects lasting beyond treatment cessation.
How it works
BLIS K12 functions primarily through the production of bacteriocins like salivaricin A2 and B, which inhibit growth of pathogenic bacteria such as *Streptococcus pyogenes*. It influences immune responses by enhancing levels of interferon-γ and decreasing IL-8 release. The strain colonizes the nasopharynx, enabling lasting effects that can continue for weeks following discontinuation of the probiotic.
Side effects
Overall, BLIS K12 has a favorable safety profile, with no significant side effects reported in research. Mild gastrointestinal symptoms have been occasionally noted, although these are not well-documented and typically occur infrequently (less than 5%). There have been no severe adverse events linked to its use in both animal and human studies. The safety of BLIS K12 is established for general populations, including children, but data is limited concerning pregnant or immunocompromised individuals. No drug interactions or contraindications are reported.
Dosage
The usual effective dosage of BLIS K12 ranges from 1 to 5 billion CFU daily. Treatment often continues for a duration of 90 days or longer. There is no established upper limit for dosage, but doses up to 5 billion CFU appear safe based on current studies. Timing of administration is flexible, although taking it consistently at the same time each day is recommended for optimal colonization and effect. Typically, it comes in lozenge or tablet forms for oral intake, which facilitate absorption.
FAQs
How long does it take to see benefits?
Benefits can be observed within days to weeks of starting treatment.
Is it safe for children?
Yes, it is considered safe for children and has been used in pediatric populations.
Can it be taken with other supplements?
There is no evidence to suggest interactions with other supplements.
What results can I expect?
Users can expect a reduction in the frequency and severity of pharyngitis and related conditions.
Is it a replacement for antibiotics?
No, it should not be considered a replacement for antibiotics, but rather a preventive measure.
Research Sources
- https://www.nutrafoods.eu/index.php/nutra/article/download/30/25 – Di Pierro et al. (2014) demonstrated the effectiveness of *Streptococcus salivarius* K12 in preventing pharyngitis and pharyngotonsillitis in children through a daily administration of at least 1 billion CFU over 90 days.
- https://ascopubs.org/doi/10.1200/JCO.23.00837 – A randomized, double-blind trial (2024) showed that *Streptococcus salivarius* K12 significantly reduced severe oral mucositis in head and neck cancer patients undergoing radiotherapy.
- https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1129060/full – This review discusses BLIS K12's potential in modulating immune responses and reducing viral infections, although it emphasizes the need for more clinical evidence to fully establish its antiviral benefits.